Drugs / CD19/CD20 Dual-CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04260932 | Mar 2020 → May 2021 | lymphoma | Hebei Yanda Ludaopei Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20 Dual-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04260932 ↗ |
| Modality | Cell therapy | “CD19/CD20 Dual-CAR-T cell therapy” NCT04260932 ↗ |
| Route | Intravenous | “CD19/CD20 Dual-CAR-T cells will be intravenously infused” NCT04260932 ↗ |